Introduction {#s1}
============

Fabry disease (MIM 301500) is an X-linked genetic disorder resulting from a deficiency of α-galactosidase A (GLA; EC 3.2.1.22) activity [@pone.0084267-Desnick1]. GLA deficiency causes the progressive accumulation of glycolipids, predominantly globotriaosylceramide, in lysosomes of cells. The disease exhibits a wide range of clinical phenotypes, from the early-onset severe "classic" form to the "later-onset" milder one [@pone.0084267-Nance1]. Generally, male patients with the classic form of Fabry disease, who have little or no GLA activity, develop pain in the peripheral extremities, hypohidrosis, angiokeratomas and corneal opacities in childhood or adolescence, and manifest renal, cardiac, and cerebrovascular complications in the fourth to fifth decade of life [@pone.0084267-MacDermot1]. On the other hand, male patients with the later-onset form, who have residual GLA activity, develop heart and kidney disorders without the childhood symptoms [@pone.0084267-Nakao1]. Heterozygous Fabry females exhibit a wide spectrum of disease severity ranging from asymptomatic to presentation with the classic disease due to random X-chromosomal inactivation [@pone.0084267-MacDermot2].

The *GLA* gene is localized to Xq22.1 and encodes a precursor GLA comprising a 429-amino acid polypeptide, the enzyme being glycosylated and then processed to the mature form comprising 398 amino acids, and it exists as a homodimer in lysosomes [@pone.0084267-Desnick1]. Each monomer contains a (β/α)~8~ barrel domain containing the active site and an anti- parallel β-sheet domain [@pone.0084267-Garman1]. So far, more than 600 genetic mutations causing Fabry disease have been identified, and it is known that gross alterations, nonsense mutations, and most of the splicing mutations of the *GLA* gene lead to the classic form. However missense mutations comprising the majority of mutations result in heterogeneous phenotypes ranging from the classic form to the later-onset one.

Previously, Garman and his research group determined the GLA structure by means of X-ray crystallography and analyzed the locations of missense and nonsense mutations in the three-dimensional structure [@pone.0084267-Garman1], [@pone.0084267-Garman2]. Our research group studied structural changes caused by missense mutations responsible for Fabry disease by calculating the numbers of affected atoms and the root-mean-square distance (RMSD) values [@pone.0084267-Sugawara1], and proposed a phenotype prediction model based on sequential and structural information [@pone.0084267-Saito1].

In this study, we comprehensively examined different substitutions at the same residue in the amino acid sequence of GLA, focusing on their effects on the structural change in the enzyme protein and the clinical phenotype, as such investigation will provide us with information about the relationship between the enzyme structure and the disease.

Materials and Methods {#s2}
=====================

GLA missense mutations {#s2a}
----------------------

We collected GLA missense mutations and polymorphisms registered on the Human Gene Mutation Database (<http://www.hgmd.cf.ac.uk/>) and Fabry database (<http://fabry-database.org/>). From them, we selected cases in which more than two substitutions at the same residue in the amino acid sequence of GLA have been reported. Finally, we analyzed 157 amino acid substitutions at 67 residues in this study.

Structural modeling of mutant GLAs {#s2b}
----------------------------------

Structural models of mutant GLA monomers were built by means of homology modeling using molecular modeling software, TINKER (<http://dasher.wustl.edu/tinker/>) [@pone.0084267-Kundrot1]--[@pone.0084267-Ren1]. The crystal structure of human GLA (PDB: 1R46) [@pone.0084267-Garman1] was used as a template, and energy minimization was performed. The root-mean-square gradient value was set at 0.05 kcal/mol·Å.

Calculation of the number of atoms influenced by an amino acid substitution and the RMSD values between the wild type GLA and mutant GLAs {#s2c}
-----------------------------------------------------------------------------------------------------------------------------------------

Each mutant model was superimposed on the wild type GLA structure based on the Cα atoms by the least-square-mean fitting algorithm, in which the optimal rotations and translations are found by minimizing the sum of the squared distances among all structures in the superposition [@pone.0084267-Kabsch1]--[@pone.0084267-Saito2]. We defined that the atom was affected by an amino acid substitution when the position of the atom in a mutant differed from that in the wild type structure by more than 0.15 Å. We calculated the numbers of atoms affected in the main chain and in the side chain of the enzyme, and in the active site (E170 and E231). Then, we calculated the RMSD values between the wild type GLA and mutant GLAs [@pone.0084267-Kabsch1]--[@pone.0084267-Saito2].

Determination of the solvent-accessible surface area (ASA) value {#s2d}
----------------------------------------------------------------

The ASA value of an amino acid residue in the wild type GLA was calculated using Stride (<http://webclu.bio.wzw.tum.de/stride/>) to evaluate the location of the residue in the GLA molecule.

Coloring of the atoms influenced by an amino acid substitution {#s2e}
--------------------------------------------------------------

To determine the influence of the amino acid substitutions geographically and semi- quantitatively, coloring of the influenced atoms in the three-dimensional structure of the enzyme molecule was performed for 12 mutants (M72I, M72R, M72V, E66G, E66K, E66Q, C56G, C56F, C56Y, W236C, W236L, and W236R) as to four positions (M72, E66, C56, and W236) in the GLA structure. The colors of affected atoms were shown on the basis of the distance between the wild type and mutant one.

Statistical analysis {#s2f}
--------------------

To determine the differences in the number of the affected atoms and the RMSD value between the classic Fabry group and later-onset one, statistical analysis was performed using Excel 2013 (Microsoft, Redmond, WA) by means of one side Welch\'s *t* test, it being taken that there was a significant difference if p\<0.05. Then, power analysis (<http://www.statmethods.net/stats/power.html>) was performed using G\*POWER3 to evaluate statistical power for this Welch\'s *t* test [@pone.0084267-Faul1]. In power analysis calculation, sample sizes of two groups and significant level were set to 134, 11, and 0.05, respectively.

Results {#s3}
=======

Different substitutions at the same residue in the amino acid sequence of GLA {#s3a}
-----------------------------------------------------------------------------

We examined the numbers of affected atoms for the whole enzyme protein and for the active site, and the RMSD and ASA values. The results are shown in [Table 1](#pone-0084267-t001){ref-type="table"}. The numbers of atoms affected in the main chain and in the side chain, and the RMSD values in the classic Fabry group were 107±129 (134), 131±152 (134), and 0.089±0.074 Å (134), respectively. The values are expressed as average ± standard deviation (number of cases). On the other hand, in the later-onset Fabry group, they were 23±36 (11), 28±50 (11), and 0.033±0.038 Å (11), respectively. The statistical analysis showed significant differences between the classic Fabry group and the later-onset Fabry group in numbers of affected atoms in the main chain (P\<0.001, Welch\'s *t* test) and in the side chain (P\<0.001, Welch\'s *t* test), and RMSD (P\<0.001, Welch\'s *t* test). The results of the power analysis revealed that the estimated values of power were 0.70, 0.72, and 0.80 for numbers of affected atoms in the main chain and in the side chain, and RMSD, respectively. This suggests that the structural change resulting from the amino acid substitutions leading to the classic phenotype is essentially greater than that in the later-onset one, although there are some exceptional cases, i.e., in R112H and R301Q, the numbers of affected atoms and the RMSD values are apparently large, although the patients with these mutations exhibited the later-onset phenotype ([Table 1](#pone-0084267-t001){ref-type="table"}). Furthermore, the results revealed that there were no later-onset Fabry cases in which the structure of the active site was affected, although there were 57 affected cases among the 134 classic Fabry ones. This suggests that a defect of the active site tends to lead to the classic phenotype.

10.1371/journal.pone.0084267.t001

###### Different substitutions at the same residue of the amino acid sequence of α-galactosidase A.

![](pone.0084267.t001){#pone-0084267-t001-1}

  Genotype     Phenotype     Number of affected atoms   RMSD   ASA   Reference         
  ---------- -------------- -------------------------- ------ ----- ----------- ------ ------------------------------------------------
  N34K          Classic                165              153     0      0.196     25.7           Hum Genomics 2006, 2: 297--309
  N34S          Classic                 6                1      0      0.029     25.7         Am J Hum Genet 1993, 53: 1186--97
  P40L          Classic                 80               83     0      0.111     0.8            J Invest Med 2000, 48: 227--35
  P40S          Classic                 15               12     0      0.032     0.8             FEBS Lett 1990, 259: 353--6
  M42T          Classic                 9                9      0      0.023     3.8           Mol Genet Metab 2002, 76: 23--30
  M42V          Classic                 12               13     0      0.028     3.8           Eur J Hum Genet 1996, 4: 219--24
  G43R          Classic                413              471    12      0.177     0.0               Mol Med 2002, 8: 306--12
  G43V          Classic                219              250     1      0.126     0.0           Mol Genet Metab 2002, 76: 23--30
  H46R          Classic                 25               27     0      0.043     0.0               Mol Med 1997, 3: 174--82
  H46Y           Hetero                 83              119     0      0.088     0.0               Hum Mutat 2001, 18: 459
  R49C          Classic                125              136     0      0.109     55.3      Pharmacogenet Genomics 2008, 18: 773--80
  R49G          Classic                182              197     0      0.169     55.3              Mol Med 2002, 8: 306--12
  R49L          Classic                240              259     4      0.201     55.3           Hum Mol Genet 1994, 3: 667--9
  R49P          Classic                174              209     2      0.125     55.3              Hum Mutat 2001, 18: 459
  R49S          Classic                361              365     2      0.251     55.3          Eur J Hum Genet 1996, 4: 219--24
  C52R          Classic                195              242    15      0.136     49.0             Hum Mutat 1996, 8: 38--43
  C52S          Classic                 2                1      0      0.022     49.0           Hum Mol Genet 1994, 3: 1795--9
  C52Y          Classic                 56               75     0      0.073     49.0      Biochim Biophys Acta 2010, 1802: 247--52
  C56F          Classic                 67               78     0      0.128     38.4           Hum Mol Genet 1994, 3: 1795--9
  C56G          Classic                 51               60     0      0.131     38.4         Am J Hum Genet 1993, 53: 1186--97
  C56Y          Classic                 58               65     0      0.132     38.4          Eur J Hum Genet 1996, 4: 219--24
  E66G          Classic                 45               74     0      0.062     29.2          Am J Hum Genet 2006, 79: 31--40
  E66K          Classic                422              503     7      0.361     29.2              Hum Mutat 2005, 25: 412
  E66Q        Polymorphism              23               32     0      0.048     29.2            Hum Genet 1992, 89: 29--32.
  M72I          Classic                 38               46     0      0.054     0.0               Mol Med 2002, 8: 306--12
  M72R          Classic                145              198     1      0.119     0.0       Ned Tijdschr Geneeskd 200, 144: 2412--5
  M72V        Later-onset               7                6      0      0.026     0.0          Hum Mutat 1998, Suppl 1: S213--16
  L89P          Classic                 6                12     0      0.023     0.0               Mol Med 1997, 3: 174--82
  L89R          Classic                286              337     4      0.164     0.0            Hum Mol Genet 1994, 3: 1795--9
  D92H          Classic                324              482    14      0.140     0.2           Eur J Hum Genet 1996, 4: 219--24
  D92Y          Classic                408              580    16      0.182     0.2               Mol Med 1997, 3: 174--82
  D93G          Classic                216              264    14      0.133     0.4           Eur J Hum Genet 1996, 4: 219--24
  D93N          Classic                 60              131     8      0.073     0.4             J Mol Med 2005, 83: 647--54
  D93V          Classic                200              284    12      0.128     0.4            Hum Genomics 2006, 2: 297--309
  C94S          Classic                 20               19     0      0.031     0.6               Hum Mutat 2001, 18: 459
  C94Y          Classic                180              210     0      0.142     0.6               Mol Med 1997, 3: 174--82
  A97P          Classic                 33               31     0      0.054     9.3           Br J Dermatol 2002, 147: 545--8
  A97V        Later-onset               10               12     0      0.025     9.3               Mol Med 1997, 3: 174--82
  R100K         Classic                 37               22     0      0.043     28.8           Hum Mol Genet 1994, 3: 1795--9
  R100T         Classic                205              232     5      0.137     28.8              Mol Med 1997, 3: 174--82
  R112C         Classic                 26               40     0      0.037     26.1           J Invest Med 2000, 48: 227--35
  R112H       Later-onset               70               70     0      0.082     26.1           Hum Mol Genet 1994, 3: 1795--9
  R112S         Classic                 25               35     0      0.034     26.1            Hum Mutat 2005, 25: 299--305
  F113L       Later-onset               3                2      0      0.014     4.4               Mol Med 1997, 3: 174--82
  F113S          Hetero                 0                0      0      0.005     4.4               Hum Mutat 2001, 18: 459
  G138E         Classic                167              203     1      0.121     0.0               Mol Med 2002, 8: 306--12
  G138R         Classic                209              259     4      0.277     0.0               Mol Med 1997, 3: 174--82
  C142R         Classic                 50               89    13      0.065     37.2              Mol Med 1999, 5: 806--11
  C142Y         Classic                 18               25     9      0.046     37.2            Hum Genet 1995, 95: 557--61
  S148N         Classic                 21               25     0      0.039     0.0            J Invest Med 2000, 48: 227--35
  S148R         Classic                128              177     9      0.104     0.0               Mol Med 1997, 3: 174--82
  W162C         Classic                 35               35     0      0.045     26.1            Hum Genet 1996, 98: 719--26
  W162R         Classic                 28               44     0      0.043     26.1         Am J Hum Genet 1993, 53: 1186--97
  L166G         Classic                 91              101     1      0.081     0.6            Hum Genomics 2006, 2: 297--309
  L166V         Classic                 14               14     0      0.031     0.6             Hum Genet 1995, 95: 557--61
  D170H         Classic                236              302     8      0.120     0.0             Hum Mutat 2003 Sup, 22: 258
  D170V         Classic                 88              134     4      0.072     0.0               Mol Med 1997, 3: 174--82
  G171C         Classic                 69               85     7      0.065     4.5            J Dermatol Sci 2008, 52: 61--4
  G171D         Classic                 88              103     8      0.095     4.5             Hum Mutat 2005, 25: 299--305
  G171R         Classic                315              347    12      0.284     4.5             J Mol Med 2005, 83: 647--54
  C172F         Classic                 12               25     2      0.039     33.5            J Hum Genet 2001, 46: 192--6
  C172G         Classic                 10               7      2      0.028     33.5            Hum Mutat 2003, 22: 486--92
  C172R         Classic                 18               45     3      0.049     33.5           J Invest Med 2000, 48: 227--35
  C172Y         Classic                 12               26     2      0.041     33.5           Hum Mol Genet 1994, 3: 1795--9
  G183A          Hetero                 35               44     0      0.063     2.1       Biochim Biophys Acta 2010, 1802: 247--52
  G183D         Classic                262              296     8      0.204     2.1              Mol Med 1999, 5: 806--811
  G183S         Classic                 62              103     0      0.088     2.1           Mol Genet Metab 2002, 76: 23--30
  M187T         Classic                 0                0      0      0.006     0.0            Hum Genomics 2006, 2: 297--309
  M187V         Classic                 8                13     0      0.030     0.0            J Invest Med 2000, 48: 227--35
  S201F         Classic                 0                2      0      0.007     6.6             Hum Mutat 2005, 25: 299--305
  S201Y         Classic                 0                2      0      0.011     6.6            Hum Genomics 2006, 2: 297--309
  C202Y         Classic                382              434    12      0.209     0.0               Mol Med 1997, 3: 174--82
  C202W          Hetero                276              313     7      0.175     0.0            Hum Mol Genet 1994, 3: 503--5
  P205R         Classic                455              571     9      0.257     0.2           Mol Genet Metab 2002, 76: 23--30
  P205T         Classic                 6                16     0      0.022     0.2           Eur J Hum Genet 1996, 4: 219--24
  Y207C         Classic                 3                4      3      0.017     50.9       J Inherit Metab Dis 2009, 32: 424--40
  Y207S         Classic                 4                5      3      0.019     50.9          Mol Genet Metab 2002, 76: 23--30
  P210L       Later-onset               0                0      0      0.003     93.3                      New case
  P210S       Later-onset               0                0      0      0.003     93.3                      New case
  Y216C         Classic                 1                1      0      0.005     7.5       Biochim Biophys Acta 2010, 1802: 247--52
  Y216D         Classic                187              246     6      0.145     7.5               Mol Med 1997, 3: 174--82
  C223R         Classic                518              589    15      0.255     0.0           Mol Genet Metab 2002, 76: 23--30
  C223Y         Classic                451              546    16      0.220     0.0           Mol Genet Metab 2002, 76: 23--30
  N224D         Classic                 65               67     0      0.057     0.0          Hum Mutat 1998, Suppl 1; S288--90
  N224S         Classic                 42               47     0      0.054     0.0            J Invest Med 2000, 48: 227--35
  D231G         Classic                 20               58     3      0.045     54.9             Exp Mol Med 2009, 31: 1--7
  D231V         Classic                 22               64     3      0.041     54.9              Hum Mutat 2008, 29: 331
  D234E         Classic                 20               27     1      0.043     40.9            Hum Mutat 2005, 25: 299--305
  D234Y         Classic                352              456    13      0.270     40.9          Mol Genet Metab 2002, 76: 23--30
  S235C         Classic                 0                0      0      0.004     53.9             Mol Med 1999, 5: 806--811
  S235F         Classic                 0                1      0      0.004     53.9              Hum Mutat 2008, 29: 331
  W236C         Classic                 2                7      0      0.012     40.6          Eur J Hum Genet 1996, 4: 219--24
  W236L         Classic                 0                2      0      0.005     40.6             Mol Med 1999, 5: 806--811
  W236R         Classic                 6                23     0      0.025     40.6           Hum Genomics 2006, 2: 297--309
  D244H          Hetero                226              287     5      0.122     74.8             Mol Med 1999, 5: 806--811
  D244N         Classic                 20               42     0      0.037     74.8           Hum Mol Genet 1994, 3: 1795--9
  G258R          Hetero                 97               87     0      0.101     0.8               Hum Mutat 2001, 18: 459
  G258V         Classic                 67               67     0      0.087     0.8               Hum Mutat 2008, 29: 331
  D264V         Classic                132              194     9      0.097     11.2         Am J Hum Genet 1993, 53: 1186--97
  D264Y         Classic                103              132     6      0.087     11.2            Hum Mutat 2005, 25: 299--305
  D266E         Classic                 40               69     8      0.061     5.9               Mol Med 2002, 8: 306--12
  D266H          Hetero                445              596    16      0.200     5.9           J Investig Med 2000, 48: 227--35
  D266N         Classic                 48               75    10      0.059     5.9             Clin Genet 2000, 58: 228--33
  D266V         Classic                 26               43     7      0.039     5.9          Am J Hum Genet 1993, 53: 1186--97
  D266Y         Classic                 39               79    10      0.047     5.9           Mol Genet Metab 2008, 95: 224--8
  M267I         Classic                 75              105    16      0.095     4.2              Mol Med 1999, 5: 806--811
  M267R         Classic                132              192    15      0.097     4.2            Hum Genomics 2006, 2: 297--309
  V269A         Classic                 10               18     2      0.029     0.0            Hum Mol Genet 1993, 2: 1051--3
  V269M         Classic                113              129     8      0.104     0.0            Hum Genomics 2006, 2: 297--309
  G271C         Classic                 58               57     0      0.066     0.2           Mol Genet Metab 2002, 76: 23--30
  G271S         Classic                 45               65     0      0.057     0.2            Hum Genomics 2006, 2: 297--309
  G271V         Classic                195              239     7      0.149     0.2            Hum Genomics 2006, 2: 297--309
  N272K         Classic                 60              100     0      0.065     2.8            Hum Mol Genet 1994, 3: 1795--9
  N272S         Classic                 2                3      0      0.013     2.8          Eur J Hum Genet 2004, 12: 678--81
  Q279E       Later-onset               34               26     0      0.035     20.4             Hum Genet 1992, 89: 29--32
  Q279H         Classic                102              123     4      0.094     20.4              Hum Mutat 2001, 18: 459
  Q279R         Classic                 55               56     0      0.061     20.4            Hum Mutat 2003 Sup, 22: 258
  Q280H          Hetero                 87              104     0      0.079     0.0               Hum Mutat 2001, 18: 459
  Q280K         Classic                 30               41     0      0.040     0.0             J Mol Med 2005, 83: 647--54
  T282A         Classic                 3                0      0      0.008     1.2               Hum Mutat 2008, 29: 331
  T282N         Classic                 6                9      0      0.023     1.2             J Hum Genet 2001, 46: 192--6
  A285D         Classic                 32               29     0      0.041     0.0            Hum Genomics 2006, 2: 297--309
  A285P         Classic                 21               29     0      0.043     0.0             Hum Mutat 2005, 25: 299--305
  W287C         Classic                 16               14     0      0.028     1.6               Mol Med 1997, 3: 174--82
  W287G         Classic                 11               12     0      0.026     1.6           Eur J Hum Genet 1996, 4: 219--24
  A288D         Classic                 86               96     0      0.106     0.0            Hum Mol Genet 1994, 3: 1795--9
  A288P         Classic                 50               60     0      0.068     0.0           Mol Genet Metab 2002, 76: 23--30
  P293A         Classic                 75               58     0      0.069     2.6           Mol Genet Metab 2002, 76: 23--30
  P293T         Classic                 13               18     0      0.032     2.6            Hum Genomics 2006, 2: 297--309
  M296I       Later-onset               5                12     0      0.018     0.0           New Eng J Med 1995, 333: 288--93
  M296V       Later-onset               7                13     0      0.023     0.0          New Eng J Med 1991, 324: 395--399
  S297C         Classic                 0                1      0      0.011     0.0               Mol Med 2002, 8: 306--12
  S297F         Classic                215              268     8      0.145     0.0          Am J Hum Genet 1993, 53: 1186--97
  N298H          Hetero                140              181     0      0.089     0.0           Eur J Hum Genet 1996, 4: 219--24
  N298K         Classic                106              183     0      0.092     0.0              Hum Mutat 1996, 8: 38--43
  N298S         Classic                 18               14     0      0.029     0.0               Mol Med 1997, 3: 174--82
  R301Q       Later-onset              112              166     0      0.126     40.5          Am J Hum Genet 1990, 47: 784--9
  R301P         Classic                 73               94     0      0.074     40.5            J Hum Genet 2001, 46: 192--6
  N320K         Classic                150              154     0      0.105     0.0    Biochem Biophys Res Commun 1995, 214: 1219--24
  N320Y         Classic                239              286     0      0.183     0.0            J Invest Med 2000, 48: 227--35
  Q321E         Classic                124              144     0      0.088     42.6             Mol Med 1999, 5: 806--811
  Q321R         Classic                 22               24     0      0.034     42.6           Hum Genomics 2006, 2: 297--309
  G328A         Classic                145              139     0      0.100     0.0          Am J Hum Genet 1993, 53: 1186--97
  G328R         Classic                560              584     4      0.283     0.0              Hum Genet 1992, 89: 29--32
  G328V         Classic                222              239     0      0.160     0.0             Hum Mutat 2005, 25: 299--305
  E358A         Classic                102              175     0      0.091     90.8            Hum Mutat 2005, 25: 299--305
  E358G         Classic                 77              136     0      0.083     90.8              Mol Med 2002, 8: 306--12
  E358K         Classic                571              661     9      0.293     90.8         Hum Mutat 1998, Suppl 1: S139--40
  G373D         Classic                103              116     0      0.116     1.0               Hum Mutat 2001, 17: 353
  G373S         Classic                 1                0      0      0.004     1.0    Biochem Biophys Res Commun 1995, 214: 1219--24
  C382W          Hetero                271              265     0      0.205     0.2            Intern Med J 2002, 32: 575--84
  C382Y         Classic                241              245     0      0.203     0.2             Hum Mutat 2003 Sup, 22: 258
  P409A         Classic                 13               11     0      0.049     37.2              Hum Mutat 2001, 18: 459
  P409S         Classic                 10               4      0      0.024     37.2              Mol Med 2002, 8: 306--12
  P409T          Hetero                 21               18     0      0.078     37.2              Hum Mutat 2001, 18: 459
  T410A       Later-onset               0                0      0      0.005     18.6            Clin Genet 2003, 63: 205--9
  T410P         Classic                 77               93     0      0.089     18.6              Hum Mutat 2008, 29: 331

Classic, the classic form of Fabry disease; Later-onset, the later-onset form; Hetero, heterozygote of Fabry disease; and Polymorphism, GLA polymorphism.

Structural analysis of representative amino acid substitutions {#s3b}
--------------------------------------------------------------

We examined different amino acid substitutions at M72, E66, C56, and W236, because they are expected to provide us with useful information for elucidating the mechanism by which structural changes caused by them influence the severity of the disease and for identifying residues essential for the maintenance of proper folding. The localization of these residues in the dimer is shown in [Fig. 1](#pone-0084267-g001){ref-type="fig"}. The residues are widely distributed over the GLA molecule and are distant from the catalytic residues (D170 and D231).

![Structure of the GLA dimer and positions of the amino acid residues involved in the substitutions.\
The backbone is shown as a line. Subunit A and subunit B comprising the dimer are shown in light blue and green, respectively. The amino acids involved in the substitutions (C56, E66, M72 and W236) and the catalytic residues (D170 and D231) are indicated as a CPK model. Front view (left) and back view (right).](pone.0084267.g001){#pone-0084267-g001}

### M72 (M72I, M72R, and M72V) {#s3b1}

M72 is located on the α-helix (66--84) of the (β/α)~8~ barrel domain. The ASA value of this residue is 0 Å^2^, suggesting that it is fully buried. The numbers of atoms influenced by M72I in the main chain, side chain and active site are 38, 46 and 0, respectively, the RMSD value being 0.054 Å. The numbers of atoms influenced by M72R in the main chain, side chain and active site are 145, 198, and 1, respectively, the RMSD value being 0.119 Å. Considering the results, the structural changes in GLA caused by these amino acid substitutions are thought to be large. The patients with these mutations exhibited the classic form of Fabry disease. On the other hand, as to M72V, the numbers of atoms influenced in the main chain, side chain and active site are 7, 6 and 0, respectively, the RMSD value being 0.026 Å. This suggests that the structural change caused by M72V is small, and that it does not affect the active site. The patients with M72V exhibited the later-onset Fabry disease. Coloring of the influenced atoms allowed clear visualization of the differences in the structural changes between these cases ([Fig. 2a](#pone-0084267-g002){ref-type="fig"}).

![Coloring of the atoms in the three-dimensional structure of GLA influenced by amino acid substitutions at M72 (a), E66 (b), C56 (c), and W236 (d).\
The backbone of GLA is shown as a line. The atoms of the substituted residues are indicated as small black spheres and the influenced atoms as large spheres. The colors of the influenced atoms show the distances between the wild type and mutant ones as follows: 0.15 Å≤cyan \<0.30 Å, 0.30 Å≤green \<0.45 Å, 0.45 Å≤yellow \<0.60 Å, 0.60 Å≤orange \<0.75 Å, and red ≥0.75 Å.](pone.0084267.g002){#pone-0084267-g002}

### E66 (E66G, E66K and E66Q) {#s3b2}

E66 is located on the α-helix (66--84) of the (β/α)~8~ barrel domain. The ASA value is 29.2 Å^2^, suggesting that the residue is half-exposed to the solvent. For the E66G substitution, the numbers of atoms influenced in the main chain, side chain and active site are 45, 74, and 0, respectively, the RMSD value being 0.062 Å. For the E66K substitution, the numbers of atoms affected in the main chain, side chain and active site are 422, 503, and 7, respectively, the RMSD value being 0.361 Å. The patients with such large structural changes exhibited the classic form of Fabry disease. On the other hand, as to the E66Q substitution, which has been reported to be a functional polymorphism [@pone.0084267-Togawa1], the numbers of atoms affected in the main chain, side chain, and active site are 23, 32, and 0, respectively, the RMSD value being 0.048 Å. These results suggest that the structural change is moderate and that it does not affect the active site. [Fig. 2b](#pone-0084267-g002){ref-type="fig"} clearly shows that the structural change caused by E66Q is restricted to a small region on the molecular surface, although those caused by E66G and E66K extend over a broad area around the substituted residue.

### C56 (C56G, C56F, and C56Y) {#s3b3}

C56 is located between two α-helices (47--50 and 66--84). The ASA value of the residue is 38.4 Å^2^, suggesting that it is exposed to the solvent. The C56 residue forms a disulfide bond with C63 ([Fig. 3](#pone-0084267-g003){ref-type="fig"}), and it plays an important role in conformation of the enzyme molecule. [Fig. 2c](#pone-0084267-g002){ref-type="fig"} shows the structural changes caused by the C56G, C56F, and C56Y amino acid substitutions. These amino acid substitutions at the C56 position are predicted to disturb the formation of disulfide bond between C56 and C63, and thus the mutant proteins would be excessively degraded before they are transported to the lysosomes. All of the patients with these mutations presented the classic form of Fabry disease.

![GLA structure and residues involving a disulfide bond.\
The backbone of GLA is shown as a line. The atoms involved in the formation of a disulfide bond (C52-C94, C56-C63, C142-C172, C202-C223, and C378-C382) and the catalytic residues (D170 and D231) are shown as a CPK model. Front view (left) and back view (right).](pone.0084267.g003){#pone-0084267-g003}

### W236 (W236C, W236L, and W236R) {#s3b4}

W236 is located on the α-helix (236--247) of the (β/α)~8~ barrel domain, the ASA value being 40.6 Å^2^, suggesting that the residue is exposed to the solvent. As [Fig. 2d](#pone-0084267-g002){ref-type="fig"} shows, the structural changes caused by W236C, W236L, and W236R are small (The numbers of atom in the main chain affected by W236C, W236L, and W236R are 2, 0, and 6, respectively, and those in the side chain are 7, 2, and 23, respectively. The RMSD values for them are 0.012 Å, 0.005 Å, and 0.025 Å, respectively). None of them affects the active site. However, as W236 is located on the dimer interface of GLA ([Fig. 1](#pone-0084267-g001){ref-type="fig"}), and the side chain of W236 forms a hydrogen bond with E358 ([Fig. 4](#pone-0084267-g004){ref-type="fig"}), the amino acid substitution is thought to affect the conformation of the GLA molecule.

![The hydrogen bond between W236 and E358.\
The side chain of W236 forms a hydrogen bond with E358. The backbone of GLA is shown as a ribbon model, and W236 and E358 are indicated as a stick. The hydrogen bond is shown as a yellow dotted line. Front view (left) and back view (right).](pone.0084267.g004){#pone-0084267-g004}

Discussion {#s4}
==========

Recently, the results of newborn screening revealed a high incidence (1 in ∼1, 250--9,000) of Fabry disease [@pone.0084267-Spada1]--[@pone.0084267-Nakamura1]. As Fabry disease can be treated with recombinant human GLAs [@pone.0084267-Eng1]--[@pone.0084267-Schiffmann1], it is very important to understand the basis of the disease and to predict the outcome for patients found on screening. For this purpose, a structural study will provide us with valuable information. Garman and Garboczi reported that there are at least two classes of mutations in GLA that lead to disease progression: those near the active site and those of buried residues distant from the active site that adversely affect the folded state of the molecule, and a mild phenotype tends to be more solvent-accessible than a severe one [@pone.0084267-Garman1]. Our research group obtained essentially the same results as those of Garman and Garboczi. Our previous study revealed that structural changes in the classic Fabry group were generally large and tended to be localized to the core region or located in the functionally important region including the active site, and that those in the later-onset group were small and localized on the surface of the molecule [@pone.0084267-Sugawara1].

As further structural study, we focused on different substitutions at the same residue in the amino acid sequence of GLA, because such specific cases are useful for examining the influence of the severity of the structural changes on the disease progression and for identifying the residues important for the expression of GLA activity.

In this study, we could select 157 amino acid substitutions at 67 residues from two databases, and examined the correlation between the structural changes in GLA and the clinical phenotype. The results revealed that the structural changes leading to the later-onset Fabry disease tend to be smaller than those for the classic Fabry disease, i.e., M72 is buried and E66 is exposed to the solvent, and at both residues, amino acid substitutions causing a small structural change (M72V and E66Q) lead to later-onset Fabry disease or a functional polymorphism, and ones causing a large structural change (M72I, M72R, E66G, and E66K) result in classic Fabry disease. This study also revealed residues important for expression of the GLA activity. A structural change affecting the active site tends to lead to the classic form. C56 and W236 are thought to be involved in the formation of a disulfide bond and the dimer, respectively. Substitutions at these residues should affect proper folding and lead to classic Fabry disease, even if the structural change is small.

In conclusion, we investigated the effects of different substitutions at the same residue in the amino acid sequence of GLA on structural changes in the enzyme molecule and the clinical phenotype. The results revealed that structural changes influence the disease progression. Structural study from such a unique viewpoint is useful for elucidation of the basis of Fabry disease.
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